Fredun Pharmaceuticals Limited
NSE: FREDUN | Information Technology
Market Fundamentals
Stock Intelligence & News
Earnings call transcript: Fredun Pharmaceuticals jumps 10% after Q1 2026 surge
Earnings call transcript: Fredun Pharmaceuticals jumps 10% after Q1 2026 surge
Read Full Analysis →778% rally in five years! Multibagger pharma stock close to record high after Q1 results 2026
Fredun Pharmaceuticals share price rose over 3.5% following strong Q1 FY27 results, with net profit increasing 94.1% YoY to ₹13.13 crore. Revenue surged 90.7% YoY to ₹227.75 crore, while total expenses increased primarily due to rising raw material costs and other factors.
Read Full Analysis →Fredun Pharmaceuticals Ltd (539730)
Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 2026
Read Full Analysis →AI-Powered Alerts for Your Portfolio
Alerfo's AI classifies every news event by type, severity, and market impact — then instantly notifies you via Email & WhatsApp only for the stocks you track.
Fredun Pharmaceuticals Ltd (539730)
Newspaper Advertisement of the Un-Audited Financial Results for Quarter ended 30th June, 2026
Read Full Analysis →Fredun Pharmaceuticals Ltd (539730)
Outcome of the Board Meeting
Read Full Analysis →Fredun Pharmaceuticals Ltd (539730)
In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditor of the Company
Read Full Analysis →Bonus issue alert! Last day to buy this microcap pharma stock that rallied 200% in one year
Fredun Pharmaceuticals has fixed July 16 as the record date for its 2:1 bonus issue, making today the last day to buy the stock to qualify. The microcap pharma stock has surged nearly 200% over the past year and 84% in 2026, reflecting strong investor interest and robust business momentum.
Read Full Analysis →Fredun Pharmaceuticals board approves 2:1 bonus issue
Fredun Pharmaceuticals’ board has recommended a 2:1 bonus issue, granting two new equity shares for every one held. This decision aims to reward shareholders, reflecting management's confidence in the company’s sustained earnings growth, scalability, and long-term value creation strategy.
Read Full Analysis →Multibagger pharma stock declares 2:1 bonus shares, strong Q4 results 2026
Fredun Pharmaceuticals Limited's shares rose 3% after announcing a 2:1 bonus issue and strong Q4 financial results. The company reported a 56% rise in net profit to ₹11 crore for the March 2026 quarter, driven by robust demand across various segments.
Read Full Analysis →Buzzing stocks: BEL, Paytm, JSW Energy, NLC India, Fredun Pharma, Raymond, Pasupathi Acrylon, Innovision, Bhageria Ind
Buzzing stocks: BEL, Paytm, JSW Energy, NLC India, Fredun Pharma, Raymond, Pasupathi Acrylon, Innovision, Bhageria Ind
Read Full Analysis →Get instant alerts when FREDUN breaks news
Join investors who track Fredun Pharmaceuticals Limited on Alerfo — free plan available.
Set Free Alert →Frequently Asked Questions
What is the current trend for FREDUN?
FREDUN is currently showing a volatility profile consistent with its sector peers, with sentiment being actively monitored by Alerfo news scanners.
How can I set alerts for Fredun Pharmaceuticals Limited?
You can set real-time price and news alerts by registering on the Alerfo platform and adding FREDUN to your custom watchlist.